{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:34:39Z","timestamp":1740180879417,"version":"3.37.3"},"reference-count":18,"publisher":"Consilium Medicum","issue":"8","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Background. The problem of recurrent urinary tract infections (UTI) in patients with type 2 diabetes mellitus (DM 2) is relevant, especially when there is a combination of predisposing factors, such as female gender, history of UTI episodes, and therapy with sodium glucose cotransporter type 2 (SGLT-2) inhibitors, and the choice of effective and safe means could cause some difficulties, including ina terms of the burden of antibiotic resistance.\r\nAim. To evaluate the effectiveness and safety of the phytoproduct Canephron N for the prevention of exacerbations of recurrent cystitis and the effect on metabolic parameters in patients with type 2 diabetes taking SGLT-2 inhibitors.\r\nMaterials and methods. Prospective, randomized, open, parallel group study in 60 women. The main group took the drug Canephron N for 3 months. The main parameters for evaluating were the frequency of recurrence of cystitis, level of albuminuria and LDL-cholesterol peroxidation product  malondialdehyde.\r\nResults. Within 3 months of taking Canephron N, exacerbations of chronic cystitis were diagnosed 2 times less often, a decrease in albuminuria was found in the form of an increase in the proportion of patients with an optimal level of albuminuria by 20%, a 50% reduction in the frequency of the initial increase in albuminuria, and the absence of moderate albuminuria in all patients at the end of course of therapy. A decrease in the level of MDA by 1.4 times was noted (p=0.019).\r\nConclusion. Thus, the herbal drug Canephron N can be used for accompanying therapy and prophylactic treatment in patients with recurrent cystitis on the background of DM 2, taking SGLT-2 inhibitors. The course of therapy should last at least 3 months.<\/jats:p>","DOI":"10.26442\/00403660.2023.08.202362","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:08:10Z","timestamp":1697022490000},"page":"664-669","source":"Crossref","is-referenced-by-count":1,"title":["The effect of a medicinal plant preparation on the frequency of episodes of exacerbation of recurrent cystitis and metabolic parameters in patients with type 2 diabetes mellitus taking glyphlosins"],"prefix":"10.26442","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-7063","authenticated-orcid":false,"given":"Oksana V.","family":"Tsygankova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3772-1058","authenticated-orcid":false,"given":"Natalia E.","family":"Evdokimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6584-2060","authenticated-orcid":false,"given":"Olga V.","family":"Timoshchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1913-5231","authenticated-orcid":false,"given":"Lydmila D.","family":"Latyntseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"ref2","unstructured":"\u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u0420\u0424. \u0421\u0430\u0445\u0430\u0440\u043d\u044b\u0439 \u0434\u0438\u0430\u0431\u0435\u0442 2 \u0442\u0438\u043f\u0430 \u0443 \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445. M., 2022. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/diseases.medelement.com\/disease\/\u0441\u0430\u0445\u0430\u0440\u043d\u044b\u0439-\u0434\u0438\u0430\u0431\u0435\u0442-2-\u0442\u0438\u043f\u0430-\u0443-\u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445-\u043a\u0440-\u0440\u0444-2022\/17220. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 11.07.2023 [Clinical recommendations of the Russian Federation. Type 2 diabetes mellitus in adults. Moscow, 2022. Available at: https:\/\/diseases.medelement.com\/disease\/diabetes-mellitus-2-type-in-adults-kr-rf-2022\/17220. Accessed: 11.07.2023 (in Russian)]."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18699\/SSMJ20220601"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14341\/DM12123"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.26442\/00403660.2020.11.000581"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.65.2.246"},{"key":"ref7","unstructured":"\u041a\u0430\u043d\u0435\u0444\u0440\u043e\u043d \u041d. \u0420\u0435\u0433\u0438\u0441\u0442\u0440\u0430\u0446\u0438\u043e\u043d\u043d\u043e\u0435 \u0443\u0434\u043e\u0441\u0442\u043e\u0432\u0435\u0440\u0435\u043d\u0438\u0435. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/grls.rosminzdrav.ru\/Grls_View_v2.aspx?routingGuid=6d74e58a-dcaf-46ca-83a3-eb652e51cadf. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 11.07.2023 [Kanefron N. Registration certificate. Available at: https:\/\/grls.rosminzdrav.ru\/Grls_View_v2.aspx?routingGuid=6d74e58a-dcaf-46ca-83a3-eb652e51cadf. Accessed: 11.07.2023 (in Russian)]."},{"key":"ref8","unstructured":"\u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u0420\u0424. \u0426\u0438\u0441\u0442\u0438\u0442 \u0443 \u0436\u0435\u043d\u0449\u0438\u043d. M., 2021. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/diseases.medelement.com\/disease\/\u0446\u0438\u0441\u0442\u0438\u0442-\u0443-\u0436\u0435\u043d\u0449\u0438\u043d-\u043a\u043f-\u0440\u0444-2021\/16903. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 11.07.2023 [Clinical recommendations of the Russian Federation. Cystitis in women. Moscow, 2021. Available at: https:\/\/diseases.medelement.com\/disease\/cystitis-in-women-kp-rf-2021\/16903. Accessed: 11.07.2023 (in Russian)]."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"\u041c\u0430\u0440\u0442\u044b\u043d\u044e\u043a \u041b.\u041f., \u041c\u0430\u0440\u0442\u044b\u043d\u044e\u043a \u041b.\u041f., \u0420\u0443\u0436\u0438\u0446\u043a\u0430\u044f \u041e.\u0410., \u041c\u0430\u0440\u0442\u044b\u043d\u044e\u043a \u0415.\u0421. \u0412\u043b\u0438\u044f\u043d\u0438\u0435 \u0440\u0430\u0441\u0442\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u0433\u043e \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u041a\u0430\u043d\u0435\u0444\u0440\u043e\u043d\u00ae \u041d \u043d\u0430 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 \u0434\u0438\u0430\u0431\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u043d\u0435\u0444\u0440\u043e\u043f\u0430\u0442\u0438\u0438 \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u0441\u0430\u0445\u0430\u0440\u043d\u044b\u043c \u0434\u0438\u0430\u0431\u0435\u0442\u043e\u043c 2-\u0433\u043e \u0442\u0438\u043f\u0430: \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0441\u0440\u0430\u0432\u043d\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u0433\u043e \u043a\u043e\u0433\u043e\u0440\u0442\u043d\u043e\u0433\u043e \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f. \u041f\u043e\u0447\u043a\u0438. 2015;1(11):24-32 [Martynyuk LP, Martynyuk LP, Ruzhitskaya OA, Martynyuk ES. The effect of the herbal preparation Canephron\u00ae N on the course of diabetic nephropathy in patients with type 2 diabetes mellitus: results of a comparative cohort study. Kidneys. 2015;1(11):24-32 (in Russian)].","DOI":"10.22141\/2307-1257.0.1.11.2015.75396"},{"key":"ref10","unstructured":"\u0418\u0432\u0430\u043d\u043e\u0432 \u0414.\u0414., \u041d\u0430\u0437\u0430\u0440\u0435\u043d\u043a\u043e \u0412.\u0418., \u041a\u0443\u0448\u043d\u0438\u0440\u0435\u043d\u043a\u043e \u0421.\u0412., \u0438 \u0434\u0440. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0432\u043e\u0437\u043c\u043e\u0436\u043d\u043e\u0441\u0442\u0438 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u041a\u0430\u043d\u0435\u0444\u0440\u043e\u043d \u041d \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0439 \u043c\u043e\u0447\u0435\u0432\u044b\u0445 \u043f\u0443\u0442\u0435\u0439 \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u0441\u0430\u0445\u0430\u0440\u043d\u044b\u043c \u0434\u0438\u0430\u0431\u0435\u0442\u043e\u043c 2 \u0442\u0438\u043f\u0430 \u0438 \u043c\u0435\u0442\u0430\u0431\u043e\u043b\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u0441\u0438\u043d\u0434\u0440\u043e\u043c\u043e\u043c. \u0417\u0434\u043e\u0440\u043e\u0432\u2019\u044f \u0423\u043a\u0440\u0430\u0457\u043d\u0438 XXI \u0441\u0442\u043e\u0440\u0456\u0447\u0447\u044f. 2004;21(106):28 [Ivanov DD, Nazarenko VI, Kushnirenko SV, et al. Therapeutic potential of Canephron N in the treatment of urinary tract infections in patients with type 2 diabetes mellitus and metabolic syndrome. Health of Ukraine XXI century. 2004;21(106):28 (in Russian)]."},{"key":"ref11","unstructured":"\u0420\u0430\u0433\u0438\u043d\u043e \u042e.\u0418., \u0414\u0443\u0448\u043a\u0438\u043d \u041c.\u0418. \u0420\u0435\u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u043e\u0441\u0442\u044c \u043a \u043e\u043a\u0438\u0441\u043b\u0435\u043d\u0438\u044e \u0433\u0435\u043f\u0430\u0440\u0438\u043d\u0440\u0435\u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u044b\u0445 \u0412-\u043b\u0438\u043f\u043e\u043f\u0440\u043e\u0442\u0435\u0438\u0434\u043e\u0432 \u0441\u044b\u0432\u043e\u0440\u043e\u0442\u043a\u0438 \u043a\u0440\u043e\u0432\u0438 \u043f\u0440\u0438 \u0438\u0448\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u0441\u0435\u0440\u0434\u0446\u0430. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043b\u0430\u0431\u043e\u0440\u0430\u0442\u043e\u0440\u043d\u0430\u044f \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430. 1998;11:3-5 [Ragino YuI, Dushkin MI. Oxidation resistance of heparin-resistant B-lipoproteins in blood serum in coronary heart disease. Clinical Laboratory Diagnostics. 1998;11:3-5 (in Russian)]."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2021.05.012"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21886\/2712-8156-2022-3-4-7-24"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924"},{"key":"ref15","unstructured":"\u0426\u044b\u0433\u0430\u043d\u043a\u043e\u0432\u0430 \u041e.\u0412., \u0425\u0443\u0434\u044f\u043a\u043e\u0432\u0430 \u0410.\u0414., \u041b\u0430\u0442\u044b\u043d\u0446\u0435\u0432\u0430 \u041b.\u0414., \u041b\u043e\u0436\u043a\u0438\u043d\u0430 \u041d.\u0413. \u0421\u0435\u0440\u0434\u0435\u0447\u043d\u043e-\u0441\u043e\u0441\u0443\u0434\u0438\u0441\u0442\u044b\u0439 \u043a\u043e\u043d\u0442\u0438\u043d\u0443\u0443\u043c: \u043e\u0442 \u0444\u0430\u043a\u0442\u043e\u0440\u043e\u0432 \u0440\u0438\u0441\u043a\u0430 \u0434\u043e \u0441\u0438\u0441\u0442\u043e\u043b\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0441\u0435\u0440\u0434\u0435\u0447\u043d\u043e\u0439 \u043d\u0435\u0434\u043e\u0441\u0442\u0430\u0442\u043e\u0447\u043d\u043e\u0441\u0442\u0438. \u0410\u0442\u0435\u0440\u043e\u0441\u043a\u043b\u0435\u0440\u043e\u0437. 2017;13(4):42-6 [Tsygankova OV, Khudyakova AD, Latyntseva LD, Lozhkina NG. Cardiovascular continuum: from risk factors to systolic heart failure. Atherosclerosis. 2017;13(4):42-6 (in Russian)]."},{"key":"ref16","unstructured":"\u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u0420\u0424. \u0425\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0431\u043e\u043b\u0435\u0437\u043d\u044c \u043f\u043e\u0447\u0435\u043a. M., 2021. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: http:\/\/disuria.ru\/_ld\/10\/1042_kr21N18MZ.pdf. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 11.07.2023 [Clinical guidelines. Chronic kidney disease. Moscow, 2021. Available at: http:\/\/disuria.ru\/_ld\/10\/1042_kr21N18MZ.pdf. Accessed: 11.07.2023 (in Russian)]."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17212.1"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18565\/urology.2021.3.28-32"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/607413\/136055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/607413\/136055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:11:47Z","timestamp":1697022707000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/607413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,10,11]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2023.08.202362","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}